Pannex Therapeutics

Executive Summary

Pannex Therapeutics is a private, preclinical-stage biotechnology company developing small molecule inhibitors of Pannexin 1 (Panx1) channels. Panx1 channels are key mediators of pathological ATP release, which fuels chronic inflammation and immune amplification in neurological disorders and cancer. The company's platform aims to address large unmet medical needs by blocking this pathway. Founded in 2018 and headquartered in San Diego, Pannex is advancing a pipeline of novel therapeutics. While no specific development candidates have been disclosed, the company's innovative approach to targeting sterile inflammation positions it as a potential player in the neuro-inflammatory and immuno-oncology space. However, the lack of public data on lead compounds or clinical timelines introduces uncertainty, and the company remains in early stages with no listed funding rounds or partnerships. The executive summary highlights the company's scientific premise and strategic focus, but investors should seek further details on preclinical data and development plans.

Upcoming Catalysts (preview)

• Q1 2027Announcement of lead candidate selection and IND-enabling studies40% success
• Q2 2026Publication of preclinical proof-of-concept data in peer-reviewed journal60% success
• Q4 2026Strategic partnership or licensing deal for Panx1 program30% success